HGENQ — Humanigen Share News
0.000.00%
Last trade - 00:00- $0.00m
- -$3.10m
- $2.51m
U.S. RESEARCH ROUNDUP-Aspen Aerogels, Editas Medicine, Humanigen
U.S. STOCKS ON THE MOVE-Twist Bioscience, Box, Support.com
U.S. STOCKS ON THE MOVE-Gevo, Peloton, Quest Diagnostics
U.S. STOCKS ON THE MOVE-Moderna, Beauty Health, Boston Beer
U.S. STOCKS ON THE MOVE-GameStop, Google, Humanigen
Humanigen plunges after U.S. FDA declines emergency use approval for COVID-19 drug
U.S. FDA declines emergency use approval for Humanigen's COVID-19 drug (updated)
U.S. FDA declines emergency use approval for Humanigen's COVID-19 drug
Brief: FDA declines Humanigen's EUA Request for Lenzilumab in Hospitalized COVID Patients
U.S. RESEARCH ROUNDUP- Abcellera Biologics, Linde, Spire
Humanigen Inc reports results for the quarter ended in June - Earnings Summary
Brief: Humanigen Reports Second Quarter 2021 Financial Results
Humanigen Inc expected to post a loss of 86 cents a share - Earnings Preview
Brief: Humanigen Inc Says Lenzilumab Treatment May Provide Enhanced Likelihood Of Survival Without Ventilation In Hospitalized Black And African-American Covid-19 Patients
U.S. RESEARCH ROUNDUP- Aon, Charter Communications, Mastercard
Brief: Nih Advances Activ-5/Bet-B Trial Evaluating Lenzilumab From A Phase 2 Exploratory Study To A Phase 2/3 Study For The Treatment Of Covid-19
U.S. STOCKS ON THE MOVE-Gap, Biogen, Levi Strauss, Didi
U.S. STOCKS ON THE MOVE-Levi Strauss, Didi Global, Humanigen
Humanigen up on UK nod for accelerated rolling review of COVID-19 therapy